行情

VNDA

VNDA

万达生物制药
NASDAQ

实时行情|Nasdaq Last Sale

14.29
-0.71
-4.73%
盘后: 14.29 0 0.00% 16:00 01/24 EST
开盘
14.88
昨收
15.00
最高
15.01
最低
14.20
成交量
46.50万
成交额
--
52周最高
29.61
52周最低
11.83
市值
7.62亿
市盈率(TTM)
6.41
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

VNDA 新闻

  • Vanda Pharmaceuticals Option Alert: Mar 20 $16 Calls at the Ask: 1000 @ $1.101 vs 230 OI; Earnings 2/12 After Close [est] Ref=$15.1
  • Benzinga.5天前
  • Vandas patent challenge over its schizophrenia drug is finally over. But it's not their only generics threat.
  • American City Business Journals.01/16 19:57
  • Vanda Pharmaceuticals Wins U.S. Supreme Court Patent Ruling On Fanapt; Order By U.S. Supreme Court Ensures That '610 Patent Will Remain Exclusive At Least Through November 2, 2027
  • Reuters.01/13 19:16
  • Vanda Pharmaceuticals Wins Key U.S. Supreme Court Patent Ruling on Fanapt®
  • PR Newswire.01/13 19:11

更多

所属板块

生物技术和医学研究
-2.64%
制药与医学研究
-2.00%

热门股票

名称
价格
涨跌幅

VNDA 简况

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). HETLIOZ is in clinical development for the treatment of Pediatric Non-24, Jet Lag Disorder and Smith-Magenis Syndrome. It offers Fanapt for the treatment of schizophrenia. Fanapt has potential utility in various other disorders. Tradipitant is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is in clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. AQW051 is indicated for the treatment of central nervous system disorders.
展开

Webull提供Vanda Pharmaceuticals Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。